Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.

CT Open to Enrollment

A Phase 2 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Patients with Stage 4 Non-Small Cell Lung Cancer

This clinical trial is designed for men and women with stage 4 squamous and non-squamous (NSCLC) who have not received prior systemic therapy for the advanced disease.
   
The purpose of this study is to evaluate the safety and tolerability of EIK1001 with pembrolizumab and chemotherapy in participants with histologically confirmed Stage 4 non-squamous or squamous NSCLC.

Efficacy of Luspatercept In Clonal Cytopenias of Uncertain Significance

This clinical trial is for men and women who have been diagnosed with clonal cytopenias of uncertain significance (CCUS) that is clinically significant.

The purpose of this study is to learn whether luspatercept is successful in improving blood counts in patients with clonal cytopenias of uncertain significance (CCUS). Luspatercept is a U.S. Food and Drug Administration (FDA) -approved drug for myelodysplastic syndrome (MDS) but is not approved for CCUS.

A prospective, multicenter, single-arm, non-randomized clinical study designed to evaluate the safety and effectiveness of the Citadel Embolization Device

The purpose of this study is to evaluate the safety and effectiveness of the investigational Stryker Citadel Embolization Device for use in the treatment of patients with an aneurysm in the brain. A brain (cerebral) aneurysm is a bulging, weak area in the wall of an artery that supplies blood to the brain.

This device is an investigational device that has not been approved by the U.S. Food & Drug Administration (FDA) for treatment of this type of aneurysm. 

Implantation Mycoses in Immunocompromised Patients: a retrospective review of disease course and treatment efficacy

The primary objective of this retrospective review is to assess the disease course of implantation mycoses in immunocompromised patients when compared to patients without immunocompromise. The secondary objective is to assess demographic factors associated with patients with this diagnosis within our patient population.

Clinical Effect of Caffeine Consumption in Patients Taking Oral Terbinafine

Terbinafine is a common oral medication used for moderate to severe nail onychomycosis. On the terbinafine package insert, it states that terbinafine can reduce clearance of caffeine by 19%. However, the clinical effects of this finding in patients have yet to really be studied. The investigators of this study hypothesize that there would be significant changes in blood pressure or heart rate in patients consuming caffeine while taking terbinafine.

Habit Awareness Device for Treatment of Onychophagia

This clinical trial wants to find out if using a special bracelet that vibrates gently whenever someone with a nail-biting problem bites their nails can help them stop. The investigators are looking at adults who bite their nails a lot. If this bracelet works, it could make nail-biters bite their nails less and have a better life.
   
The main question the investigators are trying to answer is: "Does the gentle vibration from the bracelet make people bite their nails less?"
   

A randomized, double-blind, placebo-controlled study of LMN-201 for prevention of C. difficile infection recurrence (RePreve).

 The purpose of this study is to test if an investigational study drug, LMN-201, is safe and effective in treating patients with infection of the lower intestine (the colon) by bacteria called Clostridioides difficile (abbreviated C. difficile or C. diff). Individuals will be asked to be participants in this research study because they have developed an infection of their lower intestine (the colon) by bacteria called Clostridioides difficile (abbreviated C. difficile or C. diff).